Intas Pharmaceuticals has developed a stable extended release formulation of Clozapine with improved stability and solubility. The patent covers a composition with specific layers and polymers, ensuring quality and efficacy under various conditions. GlobalData’s report on Intas Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Intas Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Intas Pharmaceuticals's grant share as of February 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11918590B2) discloses a stable extended release pharmaceutical composition of Clozapine with various pharmaceutically acceptable excipients. The composition includes granules, pellets, beads, or spheroids of Clozapine with seal coat layers, an acidic coating, and an extended release coating containing specific polymers. The patent specifies the amounts of each component, the impurity levels, and the particle size of Clozapine for optimal solubility. The composition is designed to maintain the quantity and quality of Clozapine upon storage at specific temperature and humidity conditions for six months.
Furthermore, the patent details the dissolution profile of the pharmaceutical composition, ensuring controlled release characteristics over specific time intervals. The composition can be compressed into tablets or filled into capsules for oral administration. The patent emphasizes the importance of maintaining impurity levels within specified limits during storage to ensure the stability and efficacy of the extended release Clozapine formulation. The innovative formulation aims to improve patient compliance and therapeutic outcomes by providing a consistent and controlled release of Clozapine over an extended period.
To know more about GlobalData’s detailed insights on Intas Pharmaceuticals, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
